SCHEMBL1663492

SCHEMBL1663492

CC(C)[Si](Oc1ccc(C(=O)O)c(N)c1)(C(C)C)C(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.46
KDM4E B2RXH2 9/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
IDO1 P14902 1/20 0.41
TDP1 Q9NUW8 5/20 0.41
CYP3A4 P08684 2/20 0.41
ALOX15 P16050 1/20 0.41
PPM1B O75688 1/20 0.40
MAPT P10636 6/20 0.38
KMT2A Q03164 6/20 0.38
MEN1 O00255 4/20 0.38
THRB P10828 3/20 0.38
GAA P10253 3/20 0.38
POLB P06746 2/20 0.38
KDM6B O15054 1/20 0.38
KDM4A O75164 1/20 0.38
KDM4D Q6B0I6 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25513185 0.80 ALDH1A1 (0.71) ALDH1A1KDM4EHPGDHSD17B10IDO1
SCHEMBL29053386 0.78 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDHSD17B10CYP3A4
SCHEMBL1663674 0.76 BRAF (0.47) ALDH1A1KMT2AGAA
SCHEMBL147211 0.76 SMN1; SMN2 (0.54) ALDH1A1KDM4EHPGDTDP1CYP3A4
SCHEMBL7780345 0.76 ALDH1A1 (0.51) ALDH1A1KDM4EHPGDHSD17B10IDO1
SCHEMBL714478 0.76 NR4A1 (0.52) ALDH1A1KDM4EHPGDHSD17B10IDO1
SCHEMBL1665765 0.76 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDHSD17B10CYP3A4
SCHEMBL21487757 0.76 KDM4E (0.42) ALDH1A1KDM4EHPGDHSD17B10USP2
SCHEMBL10794756 0.75 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDHSD17B10IDO1
SCHEMBL1663027 0.75 ALDH1A1 (0.42) ALDH1A1KDM4EHPGDTDP1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 ALDH1A1 2499/4885KDM4E 2742/4885HPGD 969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.